CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Blood cancer therapy with synthetic receptors and CRISPR technology.
Blood cancer therapy with synthetic receptors and CRISPR technology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体（CAR）-T 和 -NK 细胞在治疗血液系统恶性肿瘤（包括白血病、淋巴瘤和骨髓瘤）方面取得了巨大成功。CRISPR 技术和其他合成受体（GPCR 和 synNotch）有助于解决一些与 CAR 基础疗法相关的局限性和挑战。本文旨在讨论如何将 CAR 与其他合成受体以及各种 CRISPR/Cas 工具整合用于血液肿瘤治疗。装备有其他合成受体的 CAR 表达细胞能够有条件地执行杀肿瘤功能，防止肿瘤逃逸免疫监视，并最大限度地减少非肿瘤脱靶毒性。我们还讨论了如何利用各种 CRISPR-Cas 工具来增强 CAR 细胞的功能和持久性。全面讨论了这些合成受体和 CRISPR 技术在血液肿瘤治疗中的进展、陷阱和未来前景。
Chimeric antigen receptor (CAR)-T and -NK cells showed great success in treating hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR technology and other synthetic receptors (GPCR and synNotch) have helped to address some of the limitations and challenges associated with CAR-based therapies.
Herein, this review aims to discuss how CAR can be integrated with other synthetic receptors and various CRISPR/Cas tools for blood cancer therapy. CAR-expressing cells equipped with other synthetic receptors can conditionally execute tumoricidal functions, prevent tumor escape from immune surveillance, and minimize non-tumor off-target toxicity.
We also discussed how various CRISPR-Cas tools can be harnessed to enhance CAR cells functionality and persistence. The advances, pitfalls, and future perspectives for these synthetic receptors and CRISPR technology in blood cancer therapy are comprehensively discussed.
MEMBER ACCOUNT
登录成功会直接打开下一页。
